# Prelude Therapeutics Inc: overview PRLD · Nasdaq · CIK 1678660 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/prld.md) · [Financials](/companies/prld/financials.md) · [Filings](/companies/prld/filings.md) · [Insiders](/companies/prld/insiders.md) Latest reported revenue: [$5.7m](/filings/0001193125-26-343475.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 11, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-343475). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [3.0](/filings/0001193125-25-275887.md) | [4.0 d](/filings/0001193125-26-099428.md) | [0.0](/filings/0001193125-26-218173.md) | [0.0](/filings/0001193125-26-343475.md) | [6.5](/filings/0001193125-25-275887.md) | [5.6 d](/filings/0001193125-26-099428.md) | [4.6](/filings/0001193125-26-218173.md) | [5.7](/filings/0001193125-26-343475.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(1145.9%)](/filings/0001193125-25-275887.md) | [(845.8%) d](/filings/0001193125-26-099428.md) | not reported | not reported | [(314.1%)](/filings/0001193125-25-275887.md) | [(307.6%) d](/filings/0001193125-26-099428.md) | [(309.5%)](/filings/0001193125-26-218173.md) | [(270.9%)](/filings/0001193125-26-343475.md) | | Net margin | % | [(1075.7%)](/filings/0001193125-25-275887.md) | [(718.3%) d](/filings/0001193125-26-099428.md) | not reported | not reported | [(303.5%)](/filings/0001193125-25-275887.md) | [(291.8%) d](/filings/0001193125-26-099428.md) | [(226.7%)](/filings/0001193125-26-343475.md) | [(244.1%)](/filings/0001193125-26-343475.md) | | Diluted EPS | $ per share | [(0.43)](/filings/0001193125-25-275887.md) | not reported | [(0.42)](/filings/0001193125-26-218173.md) | [(0.41)](/filings/0001193125-26-343475.md) | [(0.26)](/filings/0001193125-25-275887.md) | not reported | [(0.13)](/filings/0001193125-26-218173.md) | [(0.14)](/filings/0001193125-26-343475.md) | | Free cash flow | $m | [(27.4) d](/filings/0001193125-25-275887.md) | [(20.8) d](/filings/0001193125-26-099428.md) | [(34.3)](/filings/0001193125-26-218173.md) | [(26.1) d](/filings/0001193125-26-343475.md) | [(19.1) d](/filings/0001193125-25-275887.md) | [23.1 d](/filings/0001193125-26-099428.md) | [(21.7)](/filings/0001193125-26-218173.md) | [(15.6) d](/filings/0001193125-26-343475.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | [7.0](/filings/0001193125-26-099428.md) | [12.1](/filings/0001193125-26-099428.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | [(1995.9%)](/filings/0001193125-26-099428.md) | [(861.3%)](/filings/0001193125-26-099428.md) | | Net margin | % | not reported | not reported | not reported | [(1816.8%)](/filings/0001193125-26-099428.md) | [(819.6%)](/filings/0001193125-26-099428.md) | | Diluted EPS | $ per share | [(2.43)](/filings/0000950170-23-007989.md) | [(2.44)](/filings/0000950170-24-016016.md) | [(2.02)](/filings/0000950170-25-035921.md) | [(1.68)](/filings/0001193125-26-099428.md) | [(1.29)](/filings/0001193125-26-099428.md) | | Free cash flow | $m | [(85.9)](/filings/0000950170-23-007989.md) | [(86.7)](/filings/0000950170-24-016016.md) | [(111)](/filings/0000950170-25-035921.md) | [(104)](/filings/0001193125-26-099428.md) | [(56.4)](/filings/0001193125-26-099428.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/prld/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [ORBIMED ADVISORS LLC](/funds/1055951.md) | 2026-06-30 | $73.2m | 13,724,571 | | Added +2,815,315 | | [BAKER BROS. ADVISORS LP](/funds/1263508.md) | 2026-06-30 | $54.0m | 10,123,824 | | Unchanged | | [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $34.5m | 6,475,882 | | New +6,475,882 | | [Soleus Capital Management, L.P.](/funds/1802630.md) | 2026-06-30 | $18.0m | 3,378,378 | | New +3,378,378 | | [Kynam Capital Management, LP](/funds/1907884.md) | 2026-06-30 | $12.9m | 2,415,087 | | Added +822,536 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $10.7m | 2,009,445 | | Added +779,039 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $9.6m | 1,797,501 | | Added +1,475,615 | | [SPHERA FUNDS MANAGEMENT LTD.](/funds/1496201.md) | 2026-06-30 | $5.4m | 1,019,832 | | Added +461,493 | | [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $5.3m | 993,369 | | Added +69,743 | | [ADAR1 Capital Management, LLC](/funds/1940272.md) | 2026-06-30 | $4.8m | 900,900 | | Added +748,075 | ## Recent filings [All 388 filings](/companies/prld/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-10 | 07:29 ET | [8-K](/filings/0001193125-26-387232.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-387232 | | 2026-08-11 | 08:05 ET | [10-Q](/filings/0001193125-26-343475.md) | Quarterly report, period 2026-06-30 | 0001193125-26-343475 | | 2026-08-11 | 08:00 ET | [8-K](/filings/0001193125-26-343469.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-343469 | | 2026-06-10 | 16:11 ET | [8-K](/filings/0001193125-26-265835.md) | 5.07 Shareholder vote results | 0001193125-26-265835 | | 2026-05-12 | 07:19 ET | [10-Q](/filings/0001193125-26-218173.md) | Quarterly report, period 2026-03-31 | 0001193125-26-218173 | | 2026-05-12 | 07:11 ET | [8-K](/filings/0001193125-26-218162.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-218162 | | 2026-04-29 | 16:08 ET | [DEF 14A](/filings/0001193125-26-191532.md) | Proxy statement, period 2026-06-09 | 0001193125-26-191532 | | 2026-04-23 | 20:42 ET | [SCHEDULE 13D/A](/filings/0000947871-26-000463.md) | Ownership report, active investor, amended | 0000947871-26-000463 | | 2026-04-22 | 16:22 ET | [SCHEDULE 13D/A](/filings/0001104659-26-046848.md) | Ownership report, active investor, amended | 0001104659-26-046848 | | 2026-04-21 | 19:04 ET | [8-K](/filings/0001193125-26-164510.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-164510 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-099428.md), filed Mar 10, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/f4cca011-d35a-409d-8cdb-1bd7010f9fc4) ## About the filer - CIK: 1678660 - Tickers: PRLD - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.